ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

10 Fibro-Friendly Foods with a Bonus: Beautiful Skin

Fight Back! Win the War Being Waged Against Your Immune System

Studies Show that Magnesium L-threonate Improves Brain Plasticity, Leading to Direct and Significant...

The role of microbiota and intestinal permeability in the pathophysiology of autoimmune and neuroimm...

Clary Sage Oil May Be Pricey, but Its Benefits Are Priceless

Component of red wine, grapes can help to reduce inflammation, study finds

Poly MVA: A Novel Therapy for Increasing Energy, Repairing DNA, and Promoting Overall Health

Pumpkin Pie Turmeric Breakfast Smoothie - Vegan + Gluten-Free

Vitamin D supplementation extends life in mouse model of Huntington's disease

What’s Fenugreek Good For?

Print Page
Email Article

UCLA Jonsson Cancer Center Researchers Study Ways to Prevent Tobacco-Related Bladder Cancer

  [ 40 votes ]   [ Discuss This Article ] • August 29, 2002

$5.9 million National Cancer Institute grant to fund large clinical trial
testing green-tea extract, Iressa as cancer-prevention agents

Scientists and physicians at UCLA's Jonsson Cancer Center are launching on Aug. 28 a first-of-its-kind, comprehensive program to prevent smoking-related bladder cancer.

As part of the program, researchers will develop biomarker tests to help predict who will get bladder cancer, discover the molecular profile of the disease to identify those most at risk, conduct a clinical trial testing green-tea extract and the experimental drug Iressa as prevention agents, and create a tumor bank to aid in scientific research.

The five-year effort is funded through a $5.9 million cancer-prevention grant from the National Cancer Institute (NCI) to the cancer center, the department of urology and the division of urologic oncology. This is the largest prevention study in the United States to focus on bladder cancer in current and former smokers, UCLA researchers said. While it is widely known that smoking causes lung cancer, tobacco use also is a major risk factor for bladder cancer, said Dr. Arie Belldegrun, a cancer researcher, chief of the division of urologic oncology, a professor of urology and principal investigator for the project.

"We will study innovative approaches to reduce the risk of bladder cancer," Belldegrun said. "And while we'll study prevention in patients who have already had bladder cancer, our goal is to develop effective prevention strategies for people who may be at risk but who do not yet have bladder cancer."

This year, doctors will diagnose 56,500 cases of bladder cancer, most in men. In all, more than 12,600 people will die from bladder cancer. Most bladder cancer cases are smoking-related, said Dr. Robert Figlin, a Jonsson Cancer Center researcher, a professor of hematology/oncology and urology, and co-principal investigator for the study. Cigarette smokers are two to three times more likely than nonsmokers to get bladder cancer.

"What we're doing is looking for things that tell us why some people get this disease and others don't," Figlin said. "We want to decrease bladder cancer occurrence and develop molecular profiles that tell us who is most at risk."

Bladder cancer is a major health problem in the United States, ranking as the fourth most-common cancer in men and the eighth most-common in women, Belldegrun said.

"And cigarette smoking represents the single most significant, preventable cause of bladder cancer," Belldegrun said.

The $5.9 million grant is part of the NCI's chemoprevention program. Chemoprevention studies look at possible ways to prevent cancer with interventions that can include drugs, vitamins, diet, hormone therapy or other agents.

The Jonsson Cancer Center program will feature four angles of attack, bringing together physicians and scientists from different disciplines, including medicine, urology, epidemiology, biomathematics, biostatistics, pathology and surgery. The program includes:

· A clinical trial for 270 current and former smokers who have already had bladder cancer. The study, led by Dr. Allan Pantuck, an assistant professor of urology, will investigate the effectiveness of two compounds in preventing or delaying recurrence of the cancer and will divide volunteers into three arms. One group will receive green-tea extract, which has been shown in UCLA laboratories to reduce the growth of bladder cancer tumors both in animal models and in humans. The second group will receive an experimental drug called Iressa, an epidermal growth factor receptor inhibitor that also is being studied in lung and prostate cancers. The third group will receive a placebo.

· Development of a set of biomarkers for bladder cancer that can be used to predict who is likely to develop the disease. Such tests, to be developed by Drs. Zuo-Feng Zhang and Jian Yu Rao, could work similarly to the PSA test for prostate cancer.

· With Dr. Aarno Palotie of the UCLA Department of Human Genetics, discover a molecular profile of bladder cancer that will help determine susceptibility to the disease. Researchers will seek to uncover what specific genetic mutations and other abnormalities may put people at risk for bladder cancer, such as the BRCA1 and 2 genes do for breast cancer.

· Create a bladder cancer tumor bank for use by UCLA scientists from various medical and research disciplines for development of better prevention, detection and treatment methods for bladder cancer.

The bladder cancer-prevention program rounds out the Jonsson Cancer Center's effort to better prevent and treat smoking-related cancers. UCLA researchers also are studying ways to prevent lung cancer. The popular anti-inflammatory drug Celebrex is being tested in people at high risk of developing the disease, which will kill more than 154,000 American men and women this year.

One Celebrex study involves lung cancer survivors who are at high risk of experiencing a recurrence or developing a new lung cancer. The other study involves individuals who smoke and are at high risk of developing lung cancer.

"This is an important effort for UCLA, examining ways to prevent these two smoking-related cancers," Figlin said. "Together, these cancers strike more than 225,000 Americans every year, taking more than 167,000 lives."

No one yet knows the causes of bladder cancer. Risk factors besides tobacco smoking include age, being a man (men are two to three times more likely to get bladder cancer than women), family history and race (whites are two to three times more likely to get bladder cancer than blacks, Latinos or Asians). There's a 20-year latency period for smoking-related bladder cancer, UCLA researchers said, meaning it takes about 20 years for the cancer to develop in smokers and former smokers.

Symptoms of bladder cancer include blood in the urine, pain during urination and frequent urination or the need to urinate without results.

For more information on the UCLA bladder cancer-prevention study, or to volunteer for the clinical trial, please call (310) 794-7704.

For more information about UCLA's Jonsson Cancer Center, its people and resources, visit our site on the World Wide Web at

Post a Comment

Featured Products From the ProHealth Store
Vitamin D3 Extreme™ Optimized Curcumin Longvida® FibroSleep™

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments

Be the first to comment on this article!

Post a Comment

Natural Pain Relief Supplements

Featured Products

Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry
The New Dual Activation Pain Relief Cream The New Dual Activation Pain Relief Cream
The Curcumin Revolution: 'Golden' Ticket to Better Health The Curcumin Revolution: 'Golden' Ticket to Better Health
The Crucial Role CoQ10 Plays in Fibromyalgia and ME/CFS The Crucial Role CoQ10 Plays in Fibromyalgia and ME/CFS
The Remarkable Benefits of Reishi Medicinal Mushrooms The Remarkable Benefits of Reishi Medicinal Mushrooms

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map